Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2023 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
November 09, 2023 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
October 31, 2023 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
September 18, 2023 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
September 05, 2023 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
August 14, 2023 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
August 02, 2023 16:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
July 11, 2023 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
June 20, 2023 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded...
June 16, 2023 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference

SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...